[go: up one dir, main page]

FI934145A0 - Omformade monoklonala antikroppar mot en immunoglobulinisotyp - Google Patents

Omformade monoklonala antikroppar mot en immunoglobulinisotyp

Info

Publication number
FI934145A0
FI934145A0 FI934145A FI934145A FI934145A0 FI 934145 A0 FI934145 A0 FI 934145A0 FI 934145 A FI934145 A FI 934145A FI 934145 A FI934145 A FI 934145A FI 934145 A0 FI934145 A0 FI 934145A0
Authority
FI
Finland
Prior art keywords
omformade
immunoglobulinisotyp
monoclonal
mot
antikroppar mot
Prior art date
Application number
FI934145A
Other languages
English (en)
Other versions
FI934145L (fi
FI114550B (fi
Inventor
Norman Hardman
Frank Kolbinger
Jose Saldanha
Original Assignee
Ciba Geigy Ag
Tanox Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220228A external-priority patent/GB9220228D0/en
Application filed by Ciba Geigy Ag, Tanox Biosystems Inc filed Critical Ciba Geigy Ag
Publication of FI934145A0 publication Critical patent/FI934145A0/fi
Publication of FI934145L publication Critical patent/FI934145L/fi
Application granted granted Critical
Publication of FI114550B publication Critical patent/FI114550B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI934145A 1992-09-24 1993-09-22 Menetelmä immunoglobuliini-isotyyppiä vastaan suunnattujen uudelleenmuotoiltujen monoklonaalisten vasta-aineiden valmistamiseksi FI114550B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929220228A GB9220228D0 (en) 1992-09-24 1992-09-24 Reshaped monoclonal antibodies against an immunologlobulin isotype
GB9220228 1992-09-24
US95280292A 1992-09-25 1992-09-25
US95280292 1992-09-25

Publications (3)

Publication Number Publication Date
FI934145A0 true FI934145A0 (fi) 1993-09-22
FI934145L FI934145L (fi) 1994-03-25
FI114550B FI114550B (fi) 2004-11-15

Family

ID=26301683

Family Applications (2)

Application Number Title Priority Date Filing Date
FI934145A FI114550B (fi) 1992-09-24 1993-09-22 Menetelmä immunoglobuliini-isotyyppiä vastaan suunnattujen uudelleenmuotoiltujen monoklonaalisten vasta-aineiden valmistamiseksi
FI20040696A FI115838B (fi) 1992-09-24 2004-05-19 Ihmisen uusimuotoisten monoklonaalisen, IgE:lle spesifisen vasta-aineen käyttö IgE:n kvalitatiiviseen tai kvantitatiiviseen määrittämiseen

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20040696A FI115838B (fi) 1992-09-24 2004-05-19 Ihmisen uusimuotoisten monoklonaalisen, IgE:lle spesifisen vasta-aineen käyttö IgE:n kvalitatiiviseen tai kvantitatiiviseen määrittämiseen

Country Status (18)

Country Link
EP (2) EP1452542A3 (fi)
JP (2) JP3636737B2 (fi)
KR (1) KR100298608B1 (fi)
CN (2) CN1078250C (fi)
AT (1) ATE264388T1 (fi)
AU (1) AU675449B2 (fi)
CA (1) CA2106719C (fi)
CY (1) CY2583B2 (fi)
DE (1) DE69333484T2 (fi)
DK (1) DK0589840T3 (fi)
ES (1) ES2219640T3 (fi)
FI (2) FI114550B (fi)
HK (1) HK1056182A1 (fi)
IL (2) IL107049A (fi)
MX (1) MX9305920A (fi)
NO (1) NO318210B1 (fi)
NZ (1) NZ248743A (fi)
PT (1) PT589840E (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
AU7156996A (en) * 1995-09-13 1997-04-01 Genentech Inc. Methods for treatment of interstitial cystitis
US6127524A (en) * 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
AU2103699A (en) * 1998-01-29 1999-08-16 Tse Wen Chang Treating atopic dermatitis with ige antagonists
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP1900753B1 (en) 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
AU2003283137B8 (en) * 2002-11-08 2010-07-29 Ablynx N.V. Camelidae antibodies against immunoglobulin E and use thereof for the treatment of allergic disorders
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
AU2004209638B2 (en) * 2003-02-01 2011-02-03 Tanox, Inc. High affinity anti-human IgE antibodies
AU2004315197B2 (en) * 2004-02-02 2009-06-04 Tanox, Inc. Identification of novel IgE epitopes
JP5823867B2 (ja) 2008-10-29 2015-11-25 アブリンクス エン.ヴェー. 単一ドメイン抗原結合分子の製剤
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853636T3 (de) * 1987-12-31 1999-04-08 Tanox Biosystems, Inc., Houston, Tex. Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
US5104604A (en) * 1989-10-05 1992-04-14 Dexter Electronic Materials Div. Of Dexter Corp. Flame retardant epoxy molding compound, method and encapsulated device method of encapsulating a semiconductor device with a flame retardant epoxy molding compound
JP2988635B2 (ja) * 1990-09-18 1999-12-13 塩野義製薬株式会社 ヒトIgEに対するモノクローナル抗体
WO1992017207A1 (en) * 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
AU2498192A (en) * 1991-08-14 1993-03-16 Genentech Inc. Immunoglobulin variants for specific fc epsilon receptors

Also Published As

Publication number Publication date
ES2219640T3 (es) 2004-12-01
DE69333484D1 (de) 2004-05-19
ATE264388T1 (de) 2004-04-15
DK0589840T3 (da) 2004-07-26
CA2106719C (en) 2006-03-28
KR100298608B1 (ko) 2001-11-22
CN1088986A (zh) 1994-07-06
EP1452542A2 (en) 2004-09-01
FI934145L (fi) 1994-03-25
CN1428352A (zh) 2003-07-09
EP0589840B1 (en) 2004-04-14
AU675449B2 (en) 1997-02-06
DE69333484T2 (de) 2005-03-24
KR940006602A (ko) 1994-04-25
JP3718214B2 (ja) 2005-11-24
NZ248743A (en) 1995-04-27
CY2583B2 (en) 2009-11-04
PT589840E (pt) 2004-08-31
JPH06225788A (ja) 1994-08-16
JP3636737B2 (ja) 2005-04-06
CN1254487C (zh) 2006-05-03
MX9305920A (es) 1994-05-31
EP1452542A3 (en) 2007-05-02
AU4748893A (en) 1994-03-31
CA2106719A1 (en) 1994-03-25
IL107049A (en) 2006-07-05
NO933394L (no) 1994-03-25
NO933394D0 (no) 1993-09-23
FI114550B (fi) 2004-11-15
FI115838B (fi) 2005-07-29
JP2004357712A (ja) 2004-12-24
HK1056182A1 (en) 2004-02-06
IL107049A0 (en) 1993-12-28
EP0589840A1 (en) 1994-03-30
IL173988A0 (en) 2006-07-05
NO318210B1 (no) 2005-02-21
CN1078250C (zh) 2002-01-23
FI20040696L (fi) 2004-05-19

Similar Documents

Publication Publication Date Title
FI934145A0 (fi) Omformade monoklonala antikroppar mot en immunoglobulinisotyp
NO2017040I1 (no) Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC
NO991591L (no) Rekonstituert human anti-HM1.24 antistoff
FI951488L (fi) Ihmisen immuunikatoviruksen vastaiset ihmisen neutraloivat monoklonaaliset vasta-aineet
DK0758904T3 (da) Fremgangsmåder og sammensætninger til behandling af glomerulonephritis
EP0675734A4 (en) MONOCLONAL ALLERGEN-SPECIFIC IgA ANTIBODIES AND RELATED PRODUCTS FOR THE TREATMENT OF ALLERGIES.
DK0986577T3 (da) Opsonisk og beskyttende monoklonale og kimære antistoffer specifikke for lipoteichoicsyre af grampositive bakterier
ATE348113T1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
ATE347565T1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
DE59209129D1 (de) Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
ATE151078T1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
ATE1443T1 (de) Mittel zur behandlung allergischer reaktionen.
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
BR9304004A (pt) Método de tratamento de arrozal
DE69418931D1 (de) Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten
DE3786173D1 (de) Menschlicher monoklonaler antikoerper und arzneimittel zur prophylaxe und behandlung von infektioesen krankheiten.
RU95110653A (ru) Средство, стимулирующее в эксперименте синтез иммуноглобулинов
RU93035807A (ru) Способ лечения юношеского эпифизиолиса
DE59203041D1 (de) Vorrichtung für die Wärmebehandlung und den Transport von Substraten.
SE9404491D0 (sv) Process for the production of human monoclonal antibodies

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

FG Patent granted

Ref document number: 114550

Country of ref document: FI